For the first time in almost 16 years, a first-in-class agent has been introduced to manage hypertension (HTN). The FDA has approved AstraZeneca’s Baxfendy (baxdrostat), an Aldosterone Synthase Inhibitor, in combination with other medications to treat adults with inadequately controlled HTN.[1]
Prior to this announcement, the mainstay classes utilized for high blood pressure were Calcium Channel Blockers, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotension II Receptor Blockers (ARBs), and Thiazide-type diuretics.
Throughout the years, different agents in these classes have been combined into single-pill formulations. According to the American Heart Association, in 2019, over 50% of people were non-adherent to their blood pressure therapy just 1 year after initiation.[2] These single-pill, agents served as a reasonable solution to offset non-adherence by way of reducing pill burden, and improving overall outcomes. Despite the absence of innovation, these combination therapies provided an answer to one of the greatest barriers many face when trying to achieve target blood pressure goals: Adherence.
Is Baxfendy a real game changer?
In almost two decades, there hasn’t been an agent that introduces a different mechanistic approach to treating HTN –until now. Baxfendy being the first of this new class, shifts the landscape completely. Mechanistically, Bexfendy works on the same Renin-Aldosterone-Angiotension-System as ARBs and ACE inhibitors, but much earlier on in the pathway. It selectively inhibits Aldosterone synthase, subsequently decreasing aldosterone production.
Although Aldosterone is a key hormone that upregulates BP by increasing blood volume through sodium retention and potassium excretion, it also increases the pressure on blood vessels. Aldosterone over production can lead to inflammation and hardening of myocardial, renal, and vascular tissues, worsening HTN and contributing to chronic kidney disease.[3]
Who could potentially benefit the most?
Treatment-resistant hypertension is defined as uncontrolled blood pressure on 3 or more drug therapies, usually including a diuretic, at optimal doses, or controlled BP on 4 or more medications.[4] Unfortunately, that includes approximately 12.6% of Americans that are being treated for HTN.[5] Additionally, the relationship between excess aldosterone and treatment-resistant HTN has now been linked. It is estimated that Primary Aldosteronism (PA) is responsible for 20% of treatment-resistant HTN cases.[6] The Endocrine society now recommends people with newly diagnosed HTN to screen for aldosterone levels to rule out PA as the culprit.
How effective is Baxfendy?
The phase 3 BaxHTN trial had 796 participants that maintained a seated systolic blood pressure (SBP) ranging from 140mmHg – 170mmHg, despite being treated with 2 antihypertensive medications, or 3 or more medications including a diuretic. The study revealed that a 2mg dose of Baxfendy reduced SBP by 15.7mmHg, and a 1mg dose by 14.7mmHg in just 12 weeks.[7]
How easily accessible will Baxfendy be?
Currently, a 30-day supply of the novel brand name drug will cost American consumers a hefty $910. Astrazeneca provides cost-effective assistance for the uninsured, or people with commercial insurance that does not cover the entire cost of the medication. Payment assistance through the manufacturer unfortunately does not extend to federally insured participants e.g Medicare, Medicaid, VA.
Astrazeneca’s Baxfendy may be the answer to better managing HTN that we have been waiting almost 2 decades for.
[1]https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.13616
[2] https://www.astrazeneca.com/media-centre/press-releases/2026/Baxdrostat-MNR-2026.html
[3]https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.115.018226
[4] https://pmc.ncbi.nlm.nih.gov/articles/PMC4671446/
[5]https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.125.25659
[6] https://pmc.ncbi.nlm.nih.gov/articles/PMC7442120/
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa2507109
Leave a Reply